Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Articles

19384 items
12:00 AM, Oct 11, 1993  |  BioCentury | Politics, Policy & Law

Deal salvages FDA staffing

Deal salvages FDA staffing WASHINGTON - The House of Representatives, led by Democrats John Dingell of Michigan and Richard Durbin of Illinois, has forced the Clinton administration to back down on its plans to cut...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN) Salomon Brothers analyst Meirav Chovav said AMGN is fairly valued at current levels. New products won't arrive on the market until 1996, she said, with no significant earnings from them expected until...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Genzyme Corp. (GENZ) Salomon's Chovav said GENZ is entering a period of slower growth and the stock is fairly valued. According to Chovav, the company is starting to pay the price for its creative financing...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

CellPro Inc. (CPRO) Tina Rizopoulos of PaineWebber lowered her rating to "neutral" from "buy" on a price basis, saying the current price reflects CPRO's past achievements and those anticipated over the near term — expanding...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Chiron Corp. (CHIR) Even though CHIR is at an all-time high, Webber is optimistic because he believes the company's R&D organization is productive and will act as a magnet for technologies from outside. There also...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Alpha-Beta Technology Inc. (ABTI) Webber raised his rating to "strong buy" from "buy". He said positive events over the next six months will include the start of Phase III trials of Betafectin to prevent post-surgical...
12:00 AM, Oct 11, 1993  |  BioCentury | Strategy

Chiron's strategy in U.K. patent dispute

Chiron Corp. has won a court case that justifies the calculated risk it took in planning the global protection of its hepatitis C patent estate. A British court last week upheld the key portions of...
12:00 AM, Oct 11, 1993  |  BioCentury | Tools & Techniques

Isis fights antisense cynicism

Isis fights antisense cynicism Antisense technology has generated a great deal of skepticism among investors, who worry about everything from whether oligonucleotides get into cells, to manufacturing, to price. Stanley Crooke, Isis Pharmaceuticals Inc. chairman,...
12:00 AM, Oct 11, 1993  |  BioCentury | Strategy

Cruel paradox

Cruel paradox In BioCentury's on-going search for good biotech business models, we're reminded that it's possible to create a viable business that isn't really an interesting investment. The hard fact is that the bulk of...
12:00 AM, Oct 11, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Biogen Inc. (BGEN) Salomon's Chovav began coverage with a "buy," saying the company is undervalued. According to her model, the company's cash position and royalty stream are worth $31 per share. Her mid-point value estimate...

Pages